Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

Business Wire October 31, 2022

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

Business Wire September 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA - ADCT

Newsfile September 17, 2022

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Business Wire September 16, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

Accesswire September 14, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

Business Wire September 13, 2022

ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Conference

Business Wire September 6, 2022

ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes

Business Wire August 15, 2022

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Business Wire August 9, 2022

ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

Business Wire August 2, 2022

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors

Business Wire July 27, 2022

ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma

Business Wire July 20, 2022

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

Business Wire July 11, 2022

ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories

Business Wire July 8, 2022

ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors

Business Wire July 1, 2022

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

Business Wire June 29, 2022

ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

Business Wire June 13, 2022

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Business Wire June 10, 2022

ADC Therapeutics to Present at the Jefferies Healthcare Conference

Business Wire June 1, 2022

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Business Wire May 12, 2022